Eupraxia Pharmaceuticals
Cash Flow

Last updated:

Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eupraxia Pharmaceuticals generated cash of -$27,916,416, which is less than the previous year. Cash used in financing activities reached the amount of $27,842,879 last year. Net change in cash is therefore $1,078,367.

Cash Flow

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX): Cash Flow
2017 -5.29M -314.68K 9.46M
2019 -5.17M -1.89M 7.39M
2022 -18.77M 8.70M 13.52M
2023 -27.91M -99.03K 27.84M

EPRX Cash Flow Statement (2017 – 2023)

2023 2022 2019 2017
Cash at beginning of period
18.26M20.89M823.48K136.09K
Operating activities
Net income
-37.39M-23.91M-7.24M-4.99M
Adjustments to reconcile net income to cash generated by operating activities:
Depreciation and amortization
209.91K193.27K201.93K85.37K
Stock-based compensation expense
1.41M1.43M544.95K162.82K
Deferred income tax benefit 1.41M1.43M544.95K162.82K
Changes in operating assets and liabilities:
Accounts receivable, net
-139.97K310.06K135.27K-340.21K
Inventories
-577.90K-1.32M00
Accounts payable
577.90K1.32M00
Cash generated by operating activities
-27.91M-18.77M-5.17M-5.29M
Investing activities
Purchases Of Investments
0-31000
Investments In Property Plant And Equipment
-97.22K-308.37K-9.47K-314.68K
Acquisitions Net
031000
Cash generated by investing activities
-99.03K8.70M-1.89M-314.68K
Financing activities
Common Stock Issued
15.88M10.63M07.19M
Payments for dividends
0000
Repurchases of common stock
0000
Repayments of term debt
-144.43K-97.48K5.66M463.06K
Cash used in financing activities
27.84M13.52M7.39M9.46M
Net Change In Cash
1.07M3.84M332.59K3.85M
Cash at end of period
19.34M24.73M1.15M3.99M
Data sourceData sourceData sourceData source